21Sep 2021
The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update

The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update

The incretin hormones glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) have their main physiological role in augmenting insulin secretion after their nutrient‐induced secretion from the gut. GLP 1 suppresses, and GIP increases glucagon secretion, both in a glucose dependent manner. In type 2 diabetic patients, the incretin effect is reduced despite more or less normal secretion of GIP and GLP 1. Besides their role in glucose homoeostasis, the incretin hormones GIP and GLP 1 have additional biological functions: GLP 1 at pharmacological concentrations reduces appetite, food intake, and in the long run body weight, and a similar role is evolving for GIP, at least in animal studies. GIP, and to a lesser degree GLP 1, play a role in bone remodelling. One focus of this research is into the long term interaction of GIP and GLP 1 receptor signalling.

  • #endo-diabetology

Like

Save

Share